Drug Patent Watch
NOVEMBER 5, 2023
Annual Drug Patent Expirations for ACTONEL Actonel is a drug marketed by Apil and Warner Chilcott and is included in two NDAs. It is available from two suppliers. There are… The post New patent expiration for APIL drug ACTONEL appeared first on DrugPatentWatch - Make Better Decisions.
Med Ed 101
NOVEMBER 5, 2023
We are offering a ONE TIME ONLY discount of $100 on the 1 year BCPS all-access pass and I also have 10 Free Audible books to give away. ONLY the first 10 purchases will get the Free Audible version of my Drug Interaction Book (10+ hours of bonus content) as I only have a limited […] The post One Time ONLY! $100 Discount and Free Audible Book – BCPS Study Materials appeared first on Med Ed 101.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
NOVEMBER 5, 2023
With the Mastercycler X40 your daily lab routines will not only be reliable and efficient but elevated: Eppendorf’s new product offers proven reliability and the high-quality thermal cycler is now available for every lab. Discover the Mastercycler X40 and all its advantages that will raise your work to a new standard. Reproducible nucleic acid amplification and reliable temperature homogeneity are a must for Eppendorf’s Mastercycler X40 PCR cycler.
The Guardian - Pharmaceutical Industry
NOVEMBER 5, 2023
Exclusive: Regulator extends part suspension of licence to July 2024 after IT blunder led to incorrect dosage of cancer treatment A private health company paid millions by the NHS has failed to fix safety defects that led to the death of a cancer patient, the Guardian can reveal. Three patients were hospitalised and a fourth died when they were given the wrong doses of a powerful chemotherapy drug after a catastrophic IT failure at the medicine manufacturing unit of Sciensus in April this year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Express Pharma
NOVEMBER 5, 2023
Venus Remedies receives the Three Star Export House certificate from the Government of India. The “Three Star Export House” certificate is bestowed upon companies who have demonstrated consistency in their export growth and have contributed significantly to the country’s foreign trade, reaching a milestone of $100 million in a span of three years.
pharmaphorum
NOVEMBER 5, 2023
Innoviva’s ‘game changer’ antibiotic tackles gonorrhoea Phil.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
FDA Law Blog: Biosimilars
NOVEMBER 5, 2023
The 14th Asia Pacific Symposium on Cochlear Implant and Related Sciences is poised to captivate the global scientific community from November 8-11, 2023, as it convenes in Seoul, Korea. This prestigious four-day conference promises to deliver a wealth of cutting-edge insights, featuring presentations by eminent scientists and clinicians, all unified under the thought-provoking theme, “Towards Better Speech Perception and Beyond.
Drug Patent Watch
NOVEMBER 5, 2023
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-eight… The post New patent expiration for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Pharma in Brief
NOVEMBER 5, 2023
On October 19, 2023, the Ontario government proposed regulatory amendments that may eliminate the need to submit certain clinical studies and evidence when requesting that a “well-established drug” be (i) listed or (ii) designated as interchangeable on Ontario’s publicly-funded formulary. The government is seeking feedback on the proposed amendments.
Drug Patent Watch
NOVEMBER 5, 2023
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen… The post New patent expiration for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaTech
NOVEMBER 5, 2023
When a large CDMO couldn’t give a mid-size pharma company the proper attention, Adare stepped in to help manufacture CTM batches and get their project to the clinic quickly.
Drug Patent Watch
NOVEMBER 5, 2023
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty-five… The post New patent expiration for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Pharmacy Times
NOVEMBER 5, 2023
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
Pharmaceutical Technology
NOVEMBER 5, 2023
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
Pharmacy Times
NOVEMBER 5, 2023
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase II for Hyperuricemia.
Pharmacy Times
NOVEMBER 5, 2023
Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
PharmaTech
NOVEMBER 5, 2023
In this article, gain insights into how early-stage pharmaceutical product development is foundational for successful clinical trials and regulatory approvals, and why collaboration with experienced partners like CDMOs is essential.
Pharmaceutical Technology
NOVEMBER 5, 2023
XB-002 is under clinical development by Exelixis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
PharmaTech
NOVEMBER 5, 2023
A discussion of the FDA's guidance on nitrosamine impurities, various approaches for reducing the presence of impurities, and how Adare's unique nitrosamine mitigation process can help products achieve compliance.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
PharmaTech
NOVEMBER 5, 2023
To help improve adherence in children, drug developers need to consider innovative new dosage forms that can deliver flexible and convenient medications for young patients.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Drug Patent Watch
NOVEMBER 5, 2023
This chart shows the drugs with the most patents in Singapore. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Singapore? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
NOVEMBER 5, 2023
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmacy Joe
NOVEMBER 5, 2023
In this episode, I’ll discuss the frequency of awareness with paralysis in the ED. Episode 867: How common is awareness with paralysis in the ED after RSI? Subscribe on iTunes , Android , or Stitcher Rapid sequence intubation is a common procedure in the ED. After this procedure where a paralytic such as succinylcholine or rocuronium has been used along with a short-acting sedative such as propofol, ketamine, or etomidate, a definitive plan for ongoing sedation and analgesia must be made.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology
NOVEMBER 5, 2023
Birociclib is under clinical development by Sihuan Pharmaceutical Holdings Group and currently in Phase I for Solid Tumor.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-300 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Small-Cell Lung Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Bladder Cancer.
Expert insights. Personalized for you.
105 
Let's personalize your content